Inve India ▾

Invicta Diagnostic share price & results

Invicta Diagnostic Ltd· Healthcare

Results to
Mar 2026
Latest analysed call
Q4 FY26
Ownership as of
Mar 2026

Mumbai Metropolitan Region diagnostics chain (consumer brand: PC Diagnostics) offering radiology (MRI/CT/PET-CT/X-ray/ultrasound) and pathology testing through a hub-and-spoke network of centres.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue15.4 ₹ crore—Quarterly, as filedQuarter to Mar 2026Revenue from operations as filed. No quarter a year earlier is in the series, so no change is shown.
Operating margin19.4 %—Operating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points. No quarter a year earlier is in the series, so no change is shown.
Net profit0.79 ₹ crore—Quarterly, as filedQuarter to Mar 2026Profit after tax as filed. No quarter a year earlier is in the series, so no change is shown.
Return on equityUnavailable−23.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin-30.70 %−51.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable−269.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

6 targets tracked, none judged yet · 6 open · verdicts reflect calls analysed to Q4 FY26.

Invicta Diagnostic Ltd management guidance track record on Inve: 6 targets tracked across analysed earnings calls (0 achieved, 0 missed, 6 open).

TargetOriginal wordingSaidLatest callVerdict
Number of centersIncrease the number of centers by around three times over the next 3 years.
Call transcript, Q4 FY26 · 23 May 2026		Q4 FY26Q4 FY26:Announced a target to triple the number of centers over the next 3 years.
Call transcript, Q4 FY26 · 23 May 2026		New

Source: Inve Guidance Tracker for Invicta Diagnostic Ltd · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Invicta Diagnostic Ltd's 6 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹66.5 +5.56% · +₹3.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −14.1% YTD

₹60₹70₹80₹90₹100JanFebMarAprJunJulAugSeptQ4 FY26 — 22 May 2026

YTD: ₹77.4 on 1 Jan 2026 → ₹66.5. High ₹102.75 (29 Apr 2026), low ₹59.05 (4 Mar 2026).

Previous close
₹63
Market cap
₹83 Cr
52-week range
₹59.05 – ₹102.75
Price to earnings (FY ending Mar 2026)
18.63×
Return on equity (FY ending Mar 2026)
14.04%

Overview

Symbol
NSE:INVICTA
Exchange
NSE
Currency
INR

What Invicta Diagnostic Ltd does

Based on the company's own presentations, annual report and earnings calls.

Invicta Diagnostic Limited operates an integrated network of diagnostic centres across the Mumbai Metropolitan Region under the consumer brand PC Diagnostics, offering both radiology and pathology services. It runs a hub-and-spoke model: spoke centres handle basic radiology and pathology sample collection, hub centres perform advanced imaging such as MRI and CT, and a flagship centre in Thane provides full-suite diagnostics including PET-CT. Radiology — X-ray, ultrasound, CT, MRI and PET-CT — is the core of the business, with pathology (routine biochemistry and haematology tested in-house, specialised tests routed to outsourced reference laboratories) as a complementary service. Patients include individual walk-in and home-sample-collection customers as well as institutional clients such as hospitals, clinics and corporates.

Segments

  • Radiology
  • Pathology
Diagnostic centres
8 (FY26, across MMR)
Patients served
98,867 (FY26)
Tests performed
1,54,675 (FY26)
Radiology test menu
220+ tests (~96 basic + ~130 advanced)
Pathology test menu
540+ tests (~60 routine + ~487 specialised)
Tests per patient visit
1.56 (FY26)
Founded 2021Headquarters Mumbai, Maharashtra, IndiaEmployees 155 (FY26) Company website

How the price took the results

close before → close after

Q4 FY26
−5.0%
23 May

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Invicta Diagnostic Ltd

Free account: one company. Everything above stays public.

Write why you follow Invicta Diagnostic Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Invicta Diagnostic Ltd

Guides on how to read this kind of business and the numbers that matter.